And then there were 5

Last week's CHMP recommendation for approval of another biosimilar erythropoietin, coming two months after EC approval of a Sandoz biosimilar EPO, sets the stage for the first real-world test of the safety and economics of biosimilars.

Assuming the EC complies with CHMP's recommendation, there will be five biosimilar brands of erythropoietin on the European market, as well as three pioneer products...